Cytosorbents Corporation (CTSO) 株式分析

企業概要

Cytosorbents Corporation is a specialized manufacturer focused on the research, development, and commercialization of medical devices within the healthcare sector. The company leverages a proprietary blood purification technology platform that integrates adsorbent and porous polymer technologies to deliver therapeutic solutions across the United States, Germany, and international markets. Operating within the medical devices industry, the firm targets niche applications for blood purification, a segment critical for acute kidney injury management and other clinical scenarios. In terms of scale, the company carries a market capitalization of 37.99 百万ドル (37.99M), reports trailing twelve-month revenue of 37.06 百万ドル (37.06M), and employs 129 人 (129 employees). These valuation and revenue metrics indicate that Cytosorbents operates as a small-cap entity with a relatively modest revenue base compared to large-cap medical device peers, suggesting a position that relies heavily on the successful commercialization of its specific technology portfolio rather than broad market diversification.

財務健全性

The company reported trailing twelve-month revenue of 37.06 百万ドル (37.06M) alongside a net income loss of 819.8 万ドル (-8,198,000) and an EBITDA of -1274.3 万ドル (-12,743,000). The significant gap between positive revenue and substantial net income losses reveals a challenging cost structure where operating expenses and research and development expenditures heavily outweigh gross profits. Free cash flow stands at -207.18 万ドル (-2,071,875), indicating that the company is currently consuming cash reserves to fund its operations and growth initiatives rather than generating surplus liquidity. This negative cash flow position necessitates careful management of capital expenditures and working capital to maintain financial flexibility without external financing. The gross margin is robust at 71.5%, reflecting high pricing power or low cost of goods sold relative to revenue, while the operating margin sits at -43.9% and the profit margin at -22.1%, highlighting the severe impact of overhead costs and non-operating expenses on overall profitability. Liquidity analysis shows the company holds 6.25 百万ドル (6.25M) in cash against total debt of 29.11 百万ドル (29.11M), resulting in a highly leveraged debt-to-equity ratio of 493.16. Despite the high leverage, the current ratio of 2.12 suggests adequate short-term liquidity to cover immediate obligations, though the reliance on cash to service debt remains a critical risk factor. Return on equity is -96.4% and return on assets is -19.4%, metrics that clearly indicate that management has not yet generated positive returns on the capital invested by shareholders or the asset base, signaling a prolonged period of investment without corresponding earnings generation.

バリュエーション評価

Valuation metrics for Cytosorbents Corporation are distorted by its lack of earnings, as the trailing P/E ratio is listed as N/A and the forward P/E is infinite (inf). The absence of a trailing P/E implies that traditional earnings-based valuation models are inapplicable at this time, while an infinite forward P/E suggests the market does not anticipate positive earnings in the near term to justify a price-to-earnings multiple. The price-to-book ratio stands at 6.44, indicating that the market values the company's equity at a significant premium over its accounting book value, likely driven by the perceived potential of its proprietary technology despite current losses. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 1.03 and an EV/EBITDA of -4.77; the positive P/S ratio suggests investors are willing to pay one dollar for every dollar of sales, whereas the negative EV/EBITDA reflects the company's unprofitable operational status. The stock has traded between a 52-week high of 1.39 ドル and a 52-week low of 0.50 ドル, meaning the current price sits within this historical range but the specific current price relative to the high and low is not calculable without real-time data, only that it fluctuates within these bounds. The beta value of 1.48 indicates that the stock's price volatility is significantly higher than that of the broader market, moving approximately 48% more aggressively than the market index during periods of volatility.

Growth & Income

Revenue growth year-over-year is recorded at 0.9%, while earnings growth is N/A due to the company's continued losses. The disparity between the modest revenue growth and the absence of earnings growth implies that top-line expansion is not yet translating into profitability, likely due to high fixed costs and ongoing R&D investments. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it retains all earnings (or losses) to reinvest into its business operations rather than distributing income to shareholders. This retention strategy is typical for growth-oriented medical device companies in the development or early commercialization phase that prioritize funding product pipelines over shareholder returns. Overall, the growth and income profile of Cytosorbents Corporation is characterized by minimal revenue expansion and a complete absence of current earnings or dividend distributions, reflecting a business model focused on long-term technology monetization rather than immediate financial returns.